Search Results Search Sort by RelevanceMost Recent Video May 2021 Ethics Talk: Antibiotic Stewardship During COVID Dr Olivia Kates talks about appropriate use of antibiotics during the COVID-19 pandemic. Video May 2021 Ethics Talk: Equity and Intellectual Property Protection of COVID Vaccines Prof Ana Santos Rutschman talks about the impact of intellectual property regimes on domestic and global responses to the COVID-19 pandemic. Video Jan 2021 Ethics Talk: Unblinding COVID-19 Vaccine Trials Dr Steven Goodman talks about the ethical and scientific implications of breaking the blind of placebo-controlled COVID-19 vaccine trials. Video May 2020 Ethics Talk: Vaccine Ethics and the Novel Coronavirus (SARS-CoV-2) Dr Arthur Caplan talks about ethical issues surrounding the development, production, and use of potential SARS-CoV-2 vaccine. Video Jun 2021 Ethics Talk: Could Trusting Science Mean Not Trusting Some FDA Decisions? Dr Caleb Alexander examines the US Food and Drug Administration's controversial decision to approve aducanumab for the treatment of Alzheimer's Disease. Video Sep 2020 Ethics Talk: Publishing Science and Accelerating Discovery During and After COVID-19 Drs Stefano Bertozzi and Jeffrey Mackie-Mason talk about business models of scientific publishing that advance biomedical knowledge and discovery. Case and Commentary Jul 2019 Should Dialysis Be Stopped for an Unrepresented Patient With Metastatic Cancer? Adira Hulkower, JD, MS, Sarah Garijo-Garde, and Lauren S. Flicker, JD, MBE Legal inconsistencies and variation in end-of-life options generate disparities in care for unrepresented patients. AMA J Ethics. 2019;21(7):E575-581. doi: 10.1001/amajethics.2019.575. Case and Commentary Oct 2019 How Should Decision Science Inform Scarce Blood Product Allocation? Eric Kersjes, MD and Lauren B. Smith, MD Decision aids could help clinicians know when to request ethics consultation or re-evaluate blood product usage in a specific patient care situation. AMA J Ethics. 2019;21(10):E852-857. doi: 10.1001/amajethics.2019.852. Health Law Nov 2020 How Hospital Leaders and Risk Managers Can Nurture Ethics-Driven Lawyering Norine A. McGrath, MD, Evan G. DeRenzo, PhD, John K. Kilcullen, MD, JD, MPH, and Jack Schwartz, JD Hospital lawyers’ practices shape risk management operations, influence clinicians’ morale, and affect patient care. AMA J Ethics. 2020;22(11):E933-939. doi: 10.1001/amajethics.2020.933. AMA Code Says Nov 2020 AMA Code of Medical Ethics’ Opinions Related to Risk Management Ethics Scott J. Schweikart, JD, MBE and Deborah M. Eng, MS, MA Ethical dimensions of risk management are illuminated in AMA Code content on discharge planning. AMA J Ethics. 2020;22(11):E940-944. doi: 10.1001/amajethics.2020.940.
Video May 2021 Ethics Talk: Antibiotic Stewardship During COVID Dr Olivia Kates talks about appropriate use of antibiotics during the COVID-19 pandemic.
Video May 2021 Ethics Talk: Equity and Intellectual Property Protection of COVID Vaccines Prof Ana Santos Rutschman talks about the impact of intellectual property regimes on domestic and global responses to the COVID-19 pandemic.
Video Jan 2021 Ethics Talk: Unblinding COVID-19 Vaccine Trials Dr Steven Goodman talks about the ethical and scientific implications of breaking the blind of placebo-controlled COVID-19 vaccine trials.
Video May 2020 Ethics Talk: Vaccine Ethics and the Novel Coronavirus (SARS-CoV-2) Dr Arthur Caplan talks about ethical issues surrounding the development, production, and use of potential SARS-CoV-2 vaccine.
Video Jun 2021 Ethics Talk: Could Trusting Science Mean Not Trusting Some FDA Decisions? Dr Caleb Alexander examines the US Food and Drug Administration's controversial decision to approve aducanumab for the treatment of Alzheimer's Disease.
Video Sep 2020 Ethics Talk: Publishing Science and Accelerating Discovery During and After COVID-19 Drs Stefano Bertozzi and Jeffrey Mackie-Mason talk about business models of scientific publishing that advance biomedical knowledge and discovery.
Case and Commentary Jul 2019 Should Dialysis Be Stopped for an Unrepresented Patient With Metastatic Cancer? Adira Hulkower, JD, MS, Sarah Garijo-Garde, and Lauren S. Flicker, JD, MBE Legal inconsistencies and variation in end-of-life options generate disparities in care for unrepresented patients. AMA J Ethics. 2019;21(7):E575-581. doi: 10.1001/amajethics.2019.575.
Case and Commentary Oct 2019 How Should Decision Science Inform Scarce Blood Product Allocation? Eric Kersjes, MD and Lauren B. Smith, MD Decision aids could help clinicians know when to request ethics consultation or re-evaluate blood product usage in a specific patient care situation. AMA J Ethics. 2019;21(10):E852-857. doi: 10.1001/amajethics.2019.852.
Health Law Nov 2020 How Hospital Leaders and Risk Managers Can Nurture Ethics-Driven Lawyering Norine A. McGrath, MD, Evan G. DeRenzo, PhD, John K. Kilcullen, MD, JD, MPH, and Jack Schwartz, JD Hospital lawyers’ practices shape risk management operations, influence clinicians’ morale, and affect patient care. AMA J Ethics. 2020;22(11):E933-939. doi: 10.1001/amajethics.2020.933.
AMA Code Says Nov 2020 AMA Code of Medical Ethics’ Opinions Related to Risk Management Ethics Scott J. Schweikart, JD, MBE and Deborah M. Eng, MS, MA Ethical dimensions of risk management are illuminated in AMA Code content on discharge planning. AMA J Ethics. 2020;22(11):E940-944. doi: 10.1001/amajethics.2020.940.
